Compare RWAY & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RWAY | LAB |
|---|---|---|
| Founded | 2015 | 1999 |
| Country | United States | United States |
| Employees | N/A | 389 |
| Industry | | Biotechnology: Laboratory Analytical Instruments |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 274.5M | 257.2M |
| IPO Year | 2015 | 2008 |
| Metric | RWAY | LAB |
|---|---|---|
| Price | $6.70 | $0.73 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $8.11 | N/A |
| AVG Volume (30 Days) | 291.0K | ★ 758.9K |
| Earning Date | 11-05-2026 | 11-24-2026 |
| Dividend Yield | ★ 20.27% | N/A |
| EPS Growth | N/A | ★ 61.54 |
| EPS | 0.08 | ★ 0.29 |
| Revenue | N/A | ★ $101,937,000.00 |
| Revenue This Year | $2.98 | N/A |
| Revenue Next Year | $1.40 | N/A |
| P/E Ratio | $83.06 | ★ $2.26 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.19 | $0.59 |
| 52 Week High | $9.62 | $1.72 |
| Indicator | RWAY | LAB |
|---|---|---|
| Relative Strength Index (RSI) | 55.85 | 62.71 |
| Support Level | $6.31 | $0.71 |
| Resistance Level | $6.85 | $0.79 |
| Average True Range (ATR) | 0.19 | 0.04 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 81.76 | 90.33 |
Runway Growth Finance Corp is a specialty finance company focused on providing senior secured loans to high-growth-potential companies in technology, life sciences, healthcare information and services, business services, select consumer services and products, and other high-growth industries. The company has Investments in the United States, Germany, and UK, Canada, Netherlands, with the majority of its portfolio invested in the United States. The company's investment objective is to maximize its total return to its stockholders through current income on its loan portfolio, and secondarily through capital gain on its warrants and other equity positions.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.